Oncology
Page 1 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
CAR-T Cell Therapy Europe: Clinical Trials, Safety & Market Access Insights
Discover the latest insights on CAR-T Cell Therapy in Europe, focusing on clinical trials, safety profiles, and market access for hematologic cancers.
Antibody-Drug Conjugates in Breast Cancer: Enhertu vs. Trodelvy in EU Market
This article compares Enhertu and Trodelvy, two leading antibody-drug conjugates, in their effectiveness for breast cancer treatment in the EU market.
EMA Conditional Marketing Authorization: Linvoseltamab for RRMM in EU
Linvoseltamab has received EMA's Conditional Marketing Authorization for treating relapsed/refractory multiple myeloma, offering new hope for patients in the EU.
Bispecific Antibody Approvals in EU: Teclistamab & Elranatamab Review
This article reviews the recent EU approvals of teclistamab and elranatamab, highlighting their significance in treating multiple myeloma.
EMA Conditional Approvals CAR-T: Insights on Relapsed B-Cell Lymphomas
This article delves into the insights and implications of EMA's conditional approvals for CAR-T therapies in the management of relapsed B-cell lymphomas.
EMA Conditional Approval Pathway: Insights from Repotrectinib Oncology Approval
This article delves into the EMA Conditional Approval Pathway, highlighting key insights from the oncology approval of Repotrectinib for advanced cancer treatment.
European Pediatric Investigation Plans: Accelerating Oncology Drug Development Timelines
European Pediatric Investigation Plans are crucial for expediting oncology drug development, ensuring timely access to innovative treatments for pediatric cancer patients.
Real-World Evidence Oncology Drugs: EMA vs MHRA Regulatory Approaches
This article compares the EMA and MHRA's regulatory frameworks for real-world evidence in oncology drugs, focusing on their implications for cancer treatment.
Novel Immunotherapies Advanced Melanoma: EMA Approval & Phase 3 Insights
Discover the groundbreaking EMA-approved immunotherapies for advanced melanoma and insights from recent Phase 3 trials shaping future treatments.
Biosimilar Oncology Antibodies: EMA Market Dynamics & Healthcare Impact
This article delves into the market dynamics of biosimilar oncology antibodies, focusing on their role in cancer treatment and implications for healthcare systems.
EMA Conditional Approvals CAR-T: What You Need to Know on B-Cell Lymphomas
Explore the latest on EMA Conditional Approvals for CAR-T therapies targeting B-Cell Lymphomas, including treatment efficacy and patient outcomes.
EU Market Access ADCs: NICE, G-BA & HAS Assessments of Trastuzumab Deruxtecan
This article delves into the EU market access landscape for Trastuzumab Deruxtecan, focusing on assessments by NICE, G-BA, and HAS for HER2-positive cancers.